Genascence Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 5

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $11.6M

  • Investors
  • 7

Genascence General Information

Description

Developer of genetic therapy designed to provide treatment for rare disorders and tackle major prevalent diseases affecting people. The company's therapy offers the treatment of osteoarthritis disease as well as improves symptoms and reduces structural disease progression in osteoarthritis patients, enabling patients to avail improved medical care and recover quickly.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 350 Cambridge Avenue
  • Suite 300
  • Palo Alto, CA 94306
  • United States
+1 (707)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Corporate Office
  • 350 Cambridge Avenue
  • Suite 300
  • Palo Alto, CA 94306
  • United States
+1 (707)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Genascence Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Grant 23-Feb-2023 $11.6M Completed Clinical Trials - Phase 2
4. Grant 01-Apr-2022 Completed Clinical Trials - Phase 2
3. Later Stage VC (Series A) 07-Jan-2022 Completed Clinical Trials - Phase 2
2. Seed Round 29-Jul-2019 $470K $470K Completed Clinical Trials - Phase 1
1. University Spin-Out 01-Jan-2017 Completed Startup
To view Genascence’s complete valuation and funding history, request access »

Genascence Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
Seed
To view Genascence’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Genascence Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of genetic therapy designed to provide treatment for rare disorders and tackle major prevalent diseases affect
Biotechnology
Palo Alto, CA
5 As of 2025

New York, NY
 

Boston, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Genascence Competitors (23)

One of Genascence’s 23 competitors is Xalud Therapeutics, a Venture Capital-Backed company based in New York, NY.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Xalud Therapeutics Venture Capital-Backed New York, NY
Alexion Formerly VC-backed Boston, MA
Centrexion Therapeutics Venture Capital-Backed Boston, MA
NGM Biopharmaceuticals Private Equity-Backed South San Francisco, CA
Artax Biopharma Venture Capital-Backed Cambridge, MA
You’re viewing 5 of 23 competitors. Get the full list »

Genascence Patents

Genascence Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026080261-A1 Methods of treating osteoarthritis, and compositions for practicing the same Pending 07-Oct-2024
EP-4688152-A2 Methods and compositions for treating osteoarthritis Pending 31-Mar-2023
US-20260263499-A1 Methods and compositions for treating osteoarthritis Pending 31-Mar-2023
WO-2024206333-A2 Methods and compositions for treating osteoarthritis Inactive 31-Mar-2023
WO-2024206333-A3 Methods and compositions for treating osteoarthritis Inactive 31-Mar-2023 C12N15/86
To view Genascence’s complete patent history, request access »

Genascence Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Genascence Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
California Institute for Regenerative Medicine Government
United States Department of War Government Minority
Deepwork Capital Venture Capital Minority
Pacira BioSciences Corporation Minority
University of Florida Research Foundation Corporation Minority
You’re viewing 5 of 7 investors. Get the full list »

Genascence FAQs

  • When was Genascence founded?

    Genascence was founded in 2017.

  • Where is Genascence headquartered?

    Genascence is headquartered in Palo Alto, CA.

  • What is the size of Genascence?

    Genascence has 5 total employees.

  • What industry is Genascence in?

    Genascence’s primary industry is Biotechnology.

  • Is Genascence a private or public company?

    Genascence is a Private company.

  • What is Genascence’s current revenue?

    The current revenue for Genascence is .

  • How much funding has Genascence raised over time?

    Genascence has raised $10.5M.

  • Who are Genascence’s investors?

    California Institute for Regenerative Medicine, United States Department of War, Deepwork Capital, Pacira BioSciences, and University of Florida Research Foundation are 5 of 7 investors who have invested in Genascence.

  • Who are Genascence’s competitors?

    Xalud Therapeutics, Alexion, Centrexion Therapeutics, NGM Biopharmaceuticals, and Artax Biopharma are some of the 23 competitors of Genascence.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process